Sundrug CoSDGCF 79 PE Ratio (TTM) is 15.91 as of Jun. 30, 2026, which is 8% below its 10-year median of 17.37. GuruFocus rates SDGCF with a GF Score™ of 79/100 and a GF Value™ of $34.70. The stock has 1 warning sign investors should review. Among 430 Healthcare Providers & Services companies, Sundrug Co ranks better than 73.02% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-30), Sundrug Co's share price is
$28.18.
Sundrug Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.77. Therefore, Sundrug Co's PE Ratio (TTM) for today is 15.91.
Good Sign:
Sundrug Co Ltd stock PE Ratio (=14.28) is close to 10-year low of 13.29.
The historical rank and industry rank for Sundrug Co's PE Ratio (TTM) or its related term are showing as below:
SDGCF'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 13.29 Med: 17.37 Max: 26.52
Current: 14.28
During the past 13 years, the highest PE Ratio (TTM) of Sundrug Co was 26.52. The lowest was 13.29. And the median was 17.37.
SDGCF's PE Ratio (TTM) is ranked better than 73.02% of 430
companies
in the Healthcare Providers & Services industry
Industry Median: 21.48
vs SDGCF: 14.28
As of today (2026-06-30), Sundrug Co's share price is $28.18.
Sundrug Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $1.79. Therefore, Sundrug Co's PE Ratio without NRI for today is 15.78.
During the past 13 years, Sundrug Co's highestPE Ratio without NRI was 26.38. The lowest was 13.02. And the median was 17.03.
Sundrug Co's EPS without NRI for the
three
months ended in Mar. 2026 was $0.39.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $1.79.
During the past 12 months, Sundrug Co's average EPS without NRIGrowth Rate was 2.40% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 6.80% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 5.60% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 3.40% per year.
During the past 13 years, Sundrug Co's highest 3-Year average EPS without NRI Growth Rate was 46.50% per year. The lowest was -16.60% per year. And the median was 6.80% per year.
Sundrug Co's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.39.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.77.
Sundrug Co (OTCPK:SDGCF) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Sundrug Co PE Ratio (TTM) Related Terms
Sundrug Co PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Sundrug Co's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Sundrug Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sundrug Co PE Ratio (TTM) vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sundrug Co's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Sundrug Co's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Sundrug Co's PE Ratio (TTM) for today is calculated as
Sundrug Co's Share Price of today is $28.18.
Sundrug Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.77.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Sundrug Co (SDGCF) has a PE Ratio (TTM) of 15.91 as of Jun. 30, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Sundrug Co and its competitors. This is near median its historical median of 17.37. Over the past decade, Sundrug Co's PE Ratio (TTM) has ranged from 13.29 to 26.52. According to the industry distribution chart, Sundrug Co ranks #116 out of 430 companies in the Healthcare Providers & Services industry, placing it in the top 27%.
Is Sundrug Co's PE Ratio (TTM) too high?
Sundrug Co's current PE Ratio (TTM) of 15.91 is near median its 10-year median of 17.37. Over the past 10 years, this metric has ranged from a low of 13.29 to a high of 26.52. The Healthcare Providers & Services industry median PE Ratio (TTM) is 21.48. Sundrug Co's value of 15.91 is 25.9% below this industry median. Based on the distribution chart, Sundrug Co ranks #116 out of 430 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sundrug Co has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Sundrug Co's PE Ratio (TTM) compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sundrug Co ranks #116 out of 430 companies for PE Ratio (TTM). This puts Sundrug Co in the upper half of its industry. The industry median PE Ratio (TTM) is 21.48. Sundrug Co's value of 15.91 is 25.9% below this benchmark. Historically, Sundrug Co's own PE Ratio (TTM) has ranged from 13.29 to 26.52 over the past decade. While the company's 10-year median is 17.37 vs. the industry median of 21.48, Sundrug Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Healthcare Providers & Services company?
The median PE Ratio (TTM) among Healthcare Providers & Services companies is 21.48, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sundrug Co's current PE Ratio (TTM) of 15.91 is 25.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Sundrug Co and its competitors. For the Healthcare Providers & Services industry, the median PE Ratio (TTM) is 21.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sundrug Co's current PE Ratio (TTM) is 15.91, which is near median its own 10-year median of 17.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sundrug Co stock overvalued right now?
Sundrug Co (SDGCF) has a current PE Ratio (TTM) of 15.91. The stock's GF Value™ is $34.70, compared to a current price of $28.18 — trading 18.8% below its estimated fair value. The current PE Ratio (TTM) is 15.91, which is near median its 10-year median of 17.37 and 25.9% below the Healthcare Providers & Services industry median of 21.48. Sundrug Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Sundrug Co (SDGCF), the current PE Ratio (TTM) is 15.91 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sundrug Co (SDGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Sundrug Co stock appears to be undervalued.
The current stock price of $28.18 is trading 18.8% below its estimated GF Value™ of $34.70.
Key valuation signals for SDGCF:
PE Ratio (TTM): 15.91 (near median its 10-year median of 17.37)
GF Value™: $34.70 vs. price of $28.18 (18.8% below fair value)
Industry Position: 25.9% below the Healthcare Providers & Services median (#116 of 430)
No single metric tells the full story. See the SDGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sundrug Co Ltd is a Japanese-based company engaged in the operation of drug stores and discount stores. The Group operates through two segments: the Drug Store Business, which mainly sells pharmaceuticals, cosmetics, and daily necessities, and the Discount Store Business, which mainly sells food products, household goods, and other related items. It generates the majority of its revenue from the Drugstore business segment.
79GF Score
Get the complete analysis for SDGCF
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDGCF has been successfully added to your 
